At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ONCY Oncolytics Biotech Inc
Closed 11-14 16:00:00 EST
1.01
-0.02
-1.94%
盘后1.03
+0.02+1.98%
19:42 EST
High1.06
Low1.00
Vol557.19K
Open1.04
D1 Closing1.03
Amplitude5.83%
Mkt Cap77.84M
Tradable Cap74.58M
Total Shares77.07M
T/O574.32K
T/O Rate0.75%
Tradable Shares73.84M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.